GlassScriptPhysician profile
Cari Cendroski
NPI 1154939825
$2,720.21
in general payments reported to CMS, 2019-2025
23 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.12 · 2022: $230 · 2023: $292 · 2024: $1,063 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $395.18 | 2021-2025 | Lifevest |
| Amgen INC. | $352.79 | 2022-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $224.53 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $200.92 | 2024-2025 | Farxiga, Wainua |
| Abiomed | $174.09 | 2023-2025 | Impella |
| Medtronic, INC. | $151.64 | 2024 | Corevalve Evolut R |
| Heartflow, INC. | $148.21 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $145.99 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $138.73 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $137.22 | 2024-2025 | |
| Novo Nordisk INC | $136.75 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Bridgebio Pharma, INC. | $99.72 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $88.52 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.24 | 2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $64.09 | 2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $35.00 | 2025 | Synergy Ablation System |
| Terumo Medical Corporation | $31.91 | 2023 | Navicross, Angio-Seal |
| Lilly USA, LLC | $30.24 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.57 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $18.50 | 2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $15.93 | 2023 | Verquvo |
| Pfizer INC. | $15.77 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cari Cendroski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.